tirzepatide + levocarnitine brand name FDA approves tirzepatide, Eli Lilly's new type 2 diabetes drug, and the company shares an estimated price compoundedtirzepatide

Agarwal KA, Tripathi CD, Agarwal BB, Saluja S

The secondary efficacy endpoints included here are as follows: percent change in body weight at week 48

Recent reporting has highlighted the arrival of a pill-form GLP-1 option and also noted FDA scrutiny of advertising claims in this space

Current research on BPC-157 is focused on further elucidating its mechanisms of action, optimizing its therapeutic applications, and investigating its safety and efficacy in various populations and medical conditions

Further reading on observed adverse signal profiles from the investigational phase 2 programme is available in the Retatrutide Side Effects: Detailed Guide with Clinical Trial Insights 2026 article, which summarises published tolerability data for research planning purposes

You read that correctly